Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | HINT1 | P49773 | 4/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465581 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL19813683 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL12194661 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL15187537 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL471141 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL465582 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL25380147 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL15038040 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL20991026 | 1.00 | ADORA2A (0.51) | ADORA2AHPGDADORA3HINT1NT5E | |
| SCHEMBL14429192 | 0.93 | HPGD (0.52) | ADORA2AHPGDADORA3HINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2552203-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | ADORA2A 92/4885HPGD 1663/4885ADORA3 114/4885 |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885HPGD 4119/4885ADORA3 102/4885 |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885HPGD 4119/4885ADORA3 102/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | ADORA2A 55/4885HPGD 1558/4885ADORA3 82/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | ADORA2A 38/4885HPGD 2511/4885ADORA3 26/4885 |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885HPGD 4119/4885ADORA3 102/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885HPGD 4119/4885ADORA3 102/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | ADORA2A 92/4885HPGD 1663/4885ADORA3 114/4885 |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885HPGD 4119/4885ADORA3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.